肿瘤学体内 CRO 市场－全球产业规模、份额、趋势、机会和预测，按适应症（血癌、实体瘤）、按模型（同基因模型、患者来源异种移植、异种移植）、按地区和竞争情况，2020 年至 2030 年预测

2024 年全球肿瘤体内 CRO 市值为 12.4 亿美元，预计到 2030 年将以 8.29% 的复合年增长率成长。这个充满活力的行业透过提供活体模型的专业临床前和临床研究服务，在推进癌症治疗方面发挥关键作用。全球癌症负担的增加和对标靶治疗的需求推动了这一增长。体内 CRO 透过先进的测试平台和专家见解帮助製药和生物技术公司加速药物开发、提高成本效率并满足监管要求。高解析度成像、人性化模型和基于人工智慧的预测工具等技术创新正在彻底改变体内研究能力。个人化医疗的兴起正在进一步改变这一领域，CRO 会根据患者特定的基因图谱量身定制研究。 CRO、学术机构和医疗保健提供者之间的合作正在促进创新并扩大研究管道。由于肿瘤学在药物开发中仍然占据核心地位，体内 CRO 将在重塑癌症治疗中发挥越来越重要的作用。

关键市场驱动因素

癌症发生率上升

主要市场挑战

癌症研究的复杂性

主要市场趋势

个人化医疗

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球肿瘤学体内CRO市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依适应症（血癌、实体肿瘤）
  • 按模型（同基因模型、病患来源的异种移植、异种移植）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美肿瘤体内CRO市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肿瘤学体内CRO市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太地区肿瘤学体内CRO市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美肿瘤学体内CRO市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲肿瘤学体内 CRO 市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 治疗类型发布

第 13 章：全球肿瘤学体内 CRO 市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代治疗类型的威胁

第 15 章：竞争格局

• Charles River Laboratories, Inc.
• ICON PLC
• Thermo Fisher Scientific Inc.
• Eurofins Scientific SE
• Taconic Biosciences, Inc.
• Crown Biosciene, Inc.
• LabCorp
• WuXi AppTec Co., Ltd.
• Evotec SE
• The Jackson Laboratory

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Oncology Based In-vivo CRO Market was valued at USD 1.24 billion in 2024 and is projected to grow at a CAGR of 8.29% through 2030. This dynamic sector plays a critical role in advancing cancer therapeutics by providing specialized preclinical and clinical research services in live models. Growth is propelled by the increasing global burden of cancer and the demand for targeted treatments. In-vivo CROs help pharmaceutical and biotech companies accelerate drug development, improve cost efficiency, and meet regulatory demands through advanced testing platforms and expert insights. Technological innovations, such as high-resolution imaging, humanized models, and AI-based predictive tools, are revolutionizing in-vivo research capabilities. The surge in personalized medicine is further transforming the field, with CROs tailoring research to match patient-specific genetic profiles. Collaborations among CROs, academic institutions, and healthcare providers are fostering innovation and expanding the research pipeline. As oncology remains central in drug development, in-vivo CROs are set to play an increasingly vital role in reshaping cancer care.

Key Market Drivers

Rising Prevalence of Cancer

The growing incidence of cancer is significantly accelerating the expansion of the oncology-based in vivo CRO market. According to WHO 2024 data, there were 20 million new cancer cases and 9.7 million deaths in 2022, with over 53.5 million individuals living within five years of a diagnosis. This widespread impact, particularly in underserved populations, underscores a pressing need for timely and effective treatment development. As cancer's complexity increases, so does the demand for highly specialized research capabilities offered by in vivo CROs. These organizations support pharmaceutical and biotech firms in executing intricate studies that address the multifactorial nature of cancer. With advancements in personalized medicine, there's a growing reliance on CROs to develop models tailored to specific genetic profiles. The outsourcing trend is further intensified by the race to launch new therapies, pushing companies to partner with CROs to boost efficiency. In this rapidly evolving research environment, in vivo CROs provide critical infrastructure, expertise, and innovation, driving their continued growth and importance in cancer therapy development.

Key Market Challenges

Complexity of Cancer Research

The inherent complexity of cancer research presents a significant challenge to the growth of the oncology-based in vivo CRO market. With numerous cancer types, genetic mutations, and constantly shifting treatment paradigms, delivering accurate and relevant in vivo results requires a high level of specialization. Conducting studies that replicate the complex behavior of tumors within living organisms demands advanced methodologies, cutting-edge equipment, and interdisciplinary knowledge-all of which can burden the operational capacities of CROs and their clients. Furthermore, staying aligned with rapidly emerging scientific discoveries increases pressure on these organizations to continuously adapt. Successfully navigating the intricacies of genetic interactions, tumor microenvironments, and treatment responses necessitates not only technological sophistication but also a deep understanding of oncological mechanisms. This complexity limits the availability of skilled professionals, escalates costs, and lengthens research timelines, thereby posing considerable obstacles to scalability and market expansion.

Key Market Trends

Personalized Medicine

The evolution of personalized medicine is significantly influencing the growth of the oncology-based in vivo CRO market. As treatment strategies increasingly account for individual genetic and molecular profiles, the need for tailored preclinical research has grown substantially. In vivo CROs are instrumental in this shift, providing animal models that closely replicate patient-specific genetic markers and tumor behaviors. These models enable precise analysis of treatment efficacy and safety, paving the way for more accurate and effective therapeutic solutions. The complexity of this approach requires advanced tools and scientific expertise, both of which CROs are well-equipped to offer. As pharmaceutical and biotech companies aim to develop more targeted therapies with fewer side effects, they increasingly rely on CROs to conduct studies that serve as a bridge between early-stage research and clinical application. This trend highlights the expanding role of in vivo CROs in advancing precision oncology, cementing their strategic importance in the era of personalized healthcare.

Key Market Players

• Charles River Laboratories, Inc.
• ICON PLC
• Thermo Fisher Scientific Inc.
• Eurofins Scientific SE
• Taconic Biosciences, Inc.
• Crown Biosciene, Inc.
• LabCorp
• WuXi AppTec Co., Ltd.
• Evotec SE
• The Jackson Laboratory

Report Scope:

In this report, the global Oncology Based In-vivo CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Based In-vivo CRO Market, By Indication:

• Blood Cancer
• Solid Tumor

Oncology Based In-vivo CRO Market, By Model:

• Syngeneic Model
• Patient Derived Xenograft
• Xenograft

Oncology Based In-vivo CRO Market, By Region:

• North America
• Europe
• South America
• Asia Pacific
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Oncology Based In-vivo CRO Market.

Available Customizations:

Oncology Based In-vivo CRO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Based In-vivo CRO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Blood Cancer, Solid Tumor)
  • 5.2.2. By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Oncology Based In-vivo CRO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Model
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oncology Based In-vivo CRO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Model
  • 6.3.2. Canada Oncology Based In-vivo CRO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Model
  • 6.3.3. Mexico Oncology Based In-vivo CRO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Model

7. Europe Oncology Based In-vivo CRO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Model
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oncology Based In-vivo CRO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Model
  • 7.3.2. United Kingdom Oncology Based In-vivo CRO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Model
  • 7.3.3. Italy Oncology Based In-vivo CRO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Model
  • 7.3.4. France Oncology Based In-vivo CRO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Model
  • 7.3.5. Spain Oncology Based In-vivo CRO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Model

8. Asia-Pacific Oncology Based In-vivo CRO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Model
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Oncology Based In-vivo CRO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Model
  • 8.3.2. India Oncology Based In-vivo CRO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Model
  • 8.3.3. Japan Oncology Based In-vivo CRO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Model
  • 8.3.4. South Korea Oncology Based In-vivo CRO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Model
  • 8.3.5. Australia Oncology Based In-vivo CRO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Model

9. South America Oncology Based In-vivo CRO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Model
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Oncology Based In-vivo CRO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Model
  • 9.3.2. Argentina Oncology Based In-vivo CRO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Model
  • 9.3.3. Colombia Oncology Based In-vivo CRO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Model

10. Middle East and Africa Oncology Based In-vivo CRO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Model
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Oncology Based In-vivo CRO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Model
  • 10.3.2. Saudi Arabia Oncology Based In-vivo CRO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Model
  • 10.3.3. UAE Oncology Based In-vivo CRO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Model

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Treatment Type Launches

13. Global Oncology Based In-vivo CRO Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. Charles River Laboratories, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ICON PLC
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Eurofins Scientific SE
• 15.5. Taconic Biosciences, Inc.
• 15.6. Crown Biosciene, Inc.
• 15.7. LabCorp
• 15.8. WuXi AppTec Co., Ltd.
• 15.9. Evotec SE
• 15.10. The Jackson Laboratory

16. Strategic Recommendations

17. About Us & Disclaimer